Twenty-two patients (6.3%) received an FLT3 inhibitor associated with the first induction course: four patients (1.2%) received quizartinib or placebo in the QUANTUM-FIRST clinical trial (NCT02668653), and 18 patients (5.2%) received ponatinib in the PONATINIB-AML clinical trial (NCT02428543). Here, FLT3 is linked to acute myeloid leukemia.